ANN ARBOR, Mich., May 23, 2016 /PRNewswire/ -- ENDRA Inc. dba ENDRA Life Sciences (http://www.endrainc.com) announced today that it has signed a global collaboration agreement with GE Healthcare to develop ENDRA's Thermo Acoustic Enhanced UltraSound (TAEUS™).
ENDRA's TAEUS technology is being developed to enable existing ultrasound systems to visualize tissue function, composition, and monitor a variety of therapeutic interventions at the point of care. Endra believes these capabilities could have broad potential clinical applications, including non-invasively quantifying fat in the liver for diagnosis of fatty liver disease, which affects over 1 billion globally.
Under the terms of the agreement, GE Healthcare will support ENDRA's efforts to commercialize ENDRA's TAEUS technology for use in a fatty liver application by, among other things, providing equipment and technical advice, and facilitating introductions to GE Healthcare clinical ultrasound customers. In return for this assistance, ENDRA will afford GE Healthcare certain rights of first offer with respect to manufacturing and licensing rights for the target application.
"We are thrilled to partner with GE, the ultrasound market leader, to help us accelerate the development and commercialization of ENDRA's TAEUS™ technology" said Francois Michelon, ENDRA's CEO.
Discussing the collaboration agreement, Brian McEathron, GE Healthcare's Vice President and General Manager for Radiology and Vascular Ultrasound said, "GE has a long history of bringing meaningful innovation to the market, in healthcare and other sectors. We believe that ENDRA's technology has the potential to bring significant new capabilities to ultrasound – which aligns well with GE Healthcare's mission of broadening access to high-quality, cost-effective healthcare. We're very excited about working with ENDRA."
About ENDRA Life Sciences
ENDRA Life Science's mission is to bring new capabilities to ultrasound.
ENDRA's Photo-Acoustic solutions currently help global medical researchers screen and modify disease models with high image quality and volume scanning speed. ENDRA has a global installed base of leading institutions using the Nexus-128 system, the only fully 3D imaging solution for imaging anatomy, physiology and labeled molecular targets.
ENDRA's Thermo-Acoustic technology is being developed to enable clinicians to use their existing ultrasound equipment to clearly visualize tissue function, composition, and monitor a variety of therapeutic interventions – at the point of care. This directly aligns with current healthcare trends to improve patient access, clinical effectiveness, safety and cost.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/endra-announces-partnership-to-accelerate-development-of-endras-clinical-ultrasound-capabilities-300272745.html
SOURCE ENDRA Inc.